Clinical trials: Glucocorticoid-Refractory aGVHD
Cancer
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00357084
- Testing
- methotrexate, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Glucocorticosteroid Refractory Acute GVHD
Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)
The purpose of this study is to determine if Tocilizumab is a safe and effective treatment for steroid-refractory acute graft versus host disease.
- Trial name
- NCT01757197
- Testing
- Toclizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
GVHD
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD
This study aims to determine whether the fecal microbiota transplant (FMT) capsule improves the response rate of GI-aGVHD in patients with glucocorticoid-refractory acute graft vs.
- Trial name
- NCT05094765
- Testing
- FMT
- Volunteers
- 15 people
- Sponsor
- Shenzhen Xbiome Biotech Co., Ltd.
Acute GvHD
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further…
- Trial name
- ALD518-010 (NCT01530256)
- Testing
- ALD518
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- CSL Behring
Graft-vs-Host Disease
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD).
- Trial name
- NCT00032279
- Testing
- Visilizumab
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- Fred Hutchinson Cancer Center
Glucocorticoid-Refractory aGVHD
A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)
This is an open-label,single arm,Phase Ib study,in order to evaluate the safety,tolerability, preliminary efficacy and pharmacokinetics of TQ05105 tablets in subjects with Glucocorticoid-Refractory aGVHD
- Trial name
- NCT04941404
- Testing
- TQ05105 tablets
- Where
- 4 sites in China
- Volunteers
- 13 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.